GUERBET (EPA:GBT) 2009 third-quarter sales
Transparency directive : regulatory news
12/11/2009 18:09
Click here to download pdf version
PRESS RELEASE
2009 third-quarter sales
Villepinte, 13 November 2009
Consolidated Group sales (IFRS):
In thousands of euros 2009 2008 Change
First quarter.............79,031 75,573 +4.6%
Second quarter............83,485 81,376 +2.6%
Third quarter.............81,997 79,160 +3.6%
First nine months.....244,513 236,109 +3.6%
Consolidated sales by region
In thousands of euros 2009 2008 Change
European subsidiaries.......191,120 186,969 +2.2%
Other markets................53,393 49,140 +8.7%
First nine months...........244,513 236,109 +3.6%
2009 third-quarter sales highlights and outlook
Dotarem has maintained sustained growth in volume (+17.7%) and in value
(+10.1%) compared to the same period last year. This trend confirms Dotarem
position as the European leader in the MRI segment with a 38% market share
in Europe in the 2009 first half, gaining a further 5 points over the
first half of 2008.
Xenetix sales accelerated, increasing 17.3% in volume in the quarter (+4.4%
in value) to achieve yearto-date nine-month growth of 15.6% (+2.6% in value).
Reflecting this momentum, Xenetix also added market share, particularly in
Europe.
Group revenue overall in the 2009 third quarter grew 3.6%. Excluding currency
effects, revenue grew 4.1%.
Europe, the Group's primary market, experienced a period of consolidation in
the third quarter, particularly for sales to agents. The German subsidiary
has continued to deliver rapid growth in sales (+9.4%).
The Group's strongest growth has been achieved in Asia (+20.57% year-to-date),
driven notably by the expansion of sales in China.
On this basis, the Group confirms its guidance for annual sales in line with
the prior year.
Contact: Finance Department. Tel: +33 (0) 1 45 91 50 11